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Overweight and obesity lead to an increased risk for metabolic disorders such as impaired glucose regulation/insulin resistance,
dyslipidemia, and hypertension. Several molecular drug targets with potential to prevent or treat metabolic disorders have been
revealed. Interestingly, the activation of peroxisome proliferator-activated receptor (PPAR), which belongs to the nuclear receptor
superfamily, has many beneﬁcial clinical eﬀects. PPAR directly modulates gene expression by binding to a speciﬁc ligand. All PPAR
subtypes (α,γ,andδ) are involved in glucose metabolism, lipid metabolism, and energy balance. PPAR agonists play an important
role in therapeutic aspects of metabolic disorders. However, undesired eﬀects of the existing PPAR agonists have been reported. A
great deal of recent research has focused on the discovery of new PPAR modulators with more beneﬁcial eﬀects and more safety
without producing undesired side eﬀects. Herein, we brieﬂy review the roles of PPAR in metabolic disorders, the eﬀects of PPAR
modulators in metabolic disorders, and the technologies with which to discover new PPAR modulators.
Copyright © 2008 Min-Chul Cho et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. OBESITY, ADIPOCYTES, AND ADIPOKINES
Obesity, which is deﬁned as excess adiposity for a given
body size, results from an imbalance between energy intake
and energy expenditure. Body mass index (BMI), measured
as body weight in kilograms over the square of the height
in meters (kg/m2), represents a widely accepted measure of
adiposity. Wealth in industrialized societies, combined with
an often-sedentary lifestyle and plentiful, high-calorie diets,
creates irreversible weight gain. This social phenomenon can
adversely impact well-being. Due to explosive concern for
health and well-being, genes associated with human obesity
are currently being deﬁned, and whole genome scans will
soon unveil its underlying genetic loci. The various causes
of obesity are grouped according to behavioral (activity
levels, nutrition, smoking status, and socioeconomic status),
metabolic (physiological endocrine factors), and biological
(genetic,racial,gender,age,andpregnancystatus)inﬂuences
[1]. Obesity has been recognized as a chronic disease since
the National Institutes of Health Consensus conference in
1985 [2]. The increase in the prevalence of obesity has led
the World Health Organization (WHO) to recently refer to
the obesity issue as a “global epidemic”.
Chronic disruption of the energy balance due to exceed-
ing energy intake causes hypertrophy and hyperplasia of
fat cells, and this is representative of the pathology of
obesity. When the intake of energy chronically exceeds
energy expenditure, most of the excess energy is stored
in the form of triglyceride in adipose tissue (from Greek
adip-o radipo, mean fat). Increased adipose tissue mass can
arise through an increase in cell size, cell number, or both.
Adipocytes are remarkably variable in size, which reﬂects the
amount of stored triglyceride. Mild obesity mainly reﬂects
an increased adipose cell size (hypertrophic obesity), while
more severe obesity or obesity arising in childhood typically
also involves an increased number of fat cells (hyperplastic
obesity) [3]. As a key part of the homeostatic system
that controls energy balance, the molecular mechanisms
that regulate preadipose cell growth (proliferation), adipose
diﬀerentiation (adipogenesis), and lipogenesis have been
subject to extensive scrutiny. An overview of cell types and
molecular events that occur during adipogenesis is presented
in Figure 1. Preadipocytes undergo growth arrest, postcon-
ﬂuent mitosis, and clonal expansion following appropriate
environmental and gene expression cues. The committed
preadipocytes must then withdraw from the cell cycle before2 PPAR Research
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Figure 1: Adipocyte diﬀerentiation (adipogenesis) and transcriptional events in adipogenesis. A pluripotent stem cell precursor gives rise
to a multipotential mesenchymal precursor cell with a potential to diﬀerentiate into an adipocyte. The preadipocyte enters the adipogenesis
stage via environmental and gene expression signals. In an early stage of adipogenesis, major transcriptional factors such as PPARγ and
C/EBPα are expressed, and these factors strongly regulate the expressions of adipogenesis-related genes. The adipocyte secretes various
factors, including adipokines, and the secreted factors play an important role in glucose and lipid metabolism, immune system, appetite
regulation, and vascular disease. LCFAs: long-chain fatty acids; PGI2: prostacyclin; LIF: leukemia inhibitory factor; GH: growth hormone;
ADD-1: adipocyte determination and diﬀerentiation factor-1; FABPs: fatty acid-binding proteins.
adipose conversion. During the diﬀerentiation of adipocytes,
the adipocyte phenotypes are characterized by sequential
changes in the expression of numerous genes [4, 5]. The
study of the cellular and molecular events of adipogenesis
was facilitated by the establishment of preadipose cell lines.
Among these cell lines, some are derived from embryonic
cells such as the 3T3-L1 and 3T3-F442A cell lines, and others
such as the Ob17 cell line and its subclones, which originated
from adult animals [6]. When maintained in appropriate
cultureconditions,thesecellsundergoanadiposeconversion
characterized by the transcriptional activation of numerous
genes. The process of adipose conversion is controlled by
external signals, and it has been found that adipogenic
cocktails are diﬀerent depending on the cell systems used.
For instance, the 3T3-L1 preadipose cells are induced to
diﬀerentiate by a treatment with high concentrations of
cyclic AMP, dexamethasone, and insulin at the preadipose
stage. Hormones such as insulin, triiodothyronine, gluco-
corticoides, and growth hormone exert positive actions on
the diﬀerentiation of adipose cells. Prostaglandins such as
prostacyclin (PGI2), prostaglandin D2, and 15-deoxy-Δ12,14-
PGJ2 (15d-PGJ2)havealsobeenfoundtobestrongactivators
of adipogenesis. Several transcription factors have been
showntoactcooperativelyandsequentiallytocontroladipo-
genesis. These include members of the transcription factors,
such as CCAAT/enhancer-binding protein α (C/EBPα)[ 7],
peroxisome proliferator-activated receptor-γ (PPAR-γ), and
adipocyte determination, as well as diﬀerentiation factor-1
(ADD-1). The last stage of terminal diﬀerentiation corre-
sponds to the activation of several genes, including those for
proteins involved in triglyceride metabolism [8].
Adipose tissue is partitioned into a few large depots
(subcutaneous and visceral locations), and many small
depots (heart, epicardium, pericardium, large blood vessels,
major lymph nodes, bone marrow, kidney, adrenal glands,
and the brain) [9]. All adipocytes secrete a large number
of multifunctional molecules, including cytokines, growth
factors, enzymes, hormones, complement factors, matrix
proteins, and so forth. The proteins that are secreted from
adipocytes are designated “adipokines” or “adipocytokines”.
Since the isolation of the ﬁrst-known adipocyte-secreted
protein (the serine protease adipsin) in 1987 [10], the list
of adipokines has been greatly extended. Leptin (from Greek
leptos, means thin), encoded by the obese (ob)g e n e[ 6, 11],
adiponectin (also called Acrp30) [12, 13], Interleukin-6 (IL-
6), tumor necrosis factor-α (TNF-α)[ 14], resistin [15],
and visfatin [16] are candidates of great interest among
the growing number of factors found to be secreted by
adipocytes. It has recently been shown that adipokines that
are secreted from adipocytes contribute to the development
of obesity-associated metabolic disorders, including insulin
resistance, cardiovascular disease, and cancer [17].
2. METABOLIC DISORDERS AND
THERAPEUTIC TARGETS
Overweightandobesityleadtoincreasedriskfornoninsulin-
dependent diabetes, hypertension, coronary artery disease,
dyslipidemia, gallstones, osteoarthritis, sleep apnea, certain
forms of cancer, and degenerative arthritis. As the prevalence
of obesity has increased, the heterogeneous clinical disorder
strongly associated with abdominal obesity and insulin resis-
tancehasbeenidentiﬁedasamajorriskfactorforatheroscle-
roticcardiovasculardisease.Thisdisorder,previouslytermed
“syndrome X” by Reaven, and “insulin-resistance syndrome”
by others, is now considered to be metabolic syndrome
or metabolic disorder [18]. This disorder shares similar
cardiovascular risk factors, including abdominal obesity,
impaired glucose regulation/insulin resistance, dyslipidemia,
and hypertension. Accordingly, these factors deﬁne theMin-Chul Cho et al. 3
clustering of ﬁndings typical of the metabolic disorders,
and establish diagnostic criteria. A number of studies have
shown that the excess body fat that is stored in the deep
abdominal area is associated with metabolic complications
[19]. Recently, several molecular drug targets with potential
to prevent or treat metabolic disorders have been revealed.
Theexcessglucocorticoidactionbytheenzyme11β-HSD
(hydroxysteroid dehydrogenase) type 1 induces obesity and
features of metabolic disorders. Transgenic mice which are
selectively over-expressing 11β-HSD1 in adipose tissue lead
to increased food intake and body weight, as well as the
developmentofvisceralobesity.Inaddition,insulin-resistant
diabetes, hyperlipidemia, and hyperphagia were observed in
11β-HSD1 transgenic mice [20]. On the other hand, 11β-
HSD1 deﬁciency causes favorably altered fat distribution
and adipose insulin sensitization. Even with high-fat and
cholesterogenic diets, lipid proﬁles are also improved [21].
11β-HSD1 inhibitors might have beneﬁcial consequences
in metabolic disorder. For instance, carbenoxolone, an
11β-HSD1 inhibitor, reduced total cholesterol in healthy
subjects, and decreased the glucose production rate during
hyperglucagonemia in diabetic patients [22]. AMP-activated
protein kinase (AMPK) is a major regulator of lipid and
glucose metabolism, and AMPK activation appears as a
beneﬁt of exercise in diabetic patients. Activation of AMPK
by metformin decreased the level of plasma glucose and
plasma triglycerides by promoting muscle glucose uptake
and inhibiting hepatic glucose output [23]. SCD-1 (stearoyl
CoA desaturase-1) is required for the biosynthesis of the
monounsaturated fatty acids from saturated fatty acids,
and SCD-1-deﬁcient mice appear visibly lean compared to
their littermates. SCD-1 deﬁciency in ob/ob mice ameliorates
obesity and completely corrects the excessive hepatic lipid
storage and VLDL production of the hypometabolic phe-
notype in leptin deﬁciency [24]. An SCD-1 inhibitor that
reducesSCD-1activitymayserveasatherapeuticstrategyfor
metabolic disorders, but very few reports are available for the
use of SCD-1 inhibitor. IkB kinase β (IKKβ) plays a key role
in the activation of NF-kB by phosphorylating IkBα.I th a s
recently been reported to act as a key role in obesity-linked
insulin resistance. In obese rodents, increased IKK activity
or overexpressed IKK promotes insulin resistance, whereas
reduction of IKK activity or IKKβ expression improves
insulin sensitivity. In addition, high doses of IKKβ inhibitors
such as aspirin and salicylate reverse insulin resistance by
sensitizing insulin signaling in obese rodents [25]. Protein
tyrosine phosphatase 1B (PTP1B) is closely associated with
insulin signaling through the dephosphorylation of acti-
vated insulin receptor or insulin receptor substrates. PTP1B
deﬁciency and its heterozygote signiﬁcantly reduce glucose
concentrations in the blood, and PTP1B deﬁciency causes
a signiﬁcant reduction of circulating insulin concentration
compared to wild-type mice. When on a high-fat diet,
PTP1B-deﬁcient mice were resistant to diet-induced weight
gain, and remained insulin-sensitive [26]. Because PTP1B
inhibition provides attractive therapies against metabolic
disorders, various studies for the inhibition mechanism of
inhibitors against PTP1B, the structure-activity relationship,
and synthetic and pharmacological materials have been per-
formed by diﬀerent groups. Acetyl-CoA carboxylase (ACC)
isakeydeterminantofenergyhomeostasisbecauseincreased
malonyl-CoA byACC activationinhibits mitochondrial fatty
acid uptake and oxidation. A lack of malonyl-CoA in the
muscle and heart of ACC2-deﬁcient mice show increased
oxidation of fatty acid, decreased fat in adipose and liver
tissue, and decreased the storage of glycogen in the liver [27].
CP-640186, an isozyme-nonselective ACC inhibitor, inhibits
fatty acid and TG synthesis in HepG2 cells, as well as fatty
acid synthesis in obese rodents. CP-640186 also stimulates
fatty acid oxidation in C2C12 cells [28]. These eﬀects of
the ACC inhibitor may provide novel therapeutic potential
for treatment of the metabolic disorder. Interestingly, the
activation of PPARs by their ligands has many beneﬁcial
eﬀects in the improvement of glucose homeostasis and lipid
homeostasis.
3. PPARs AND METABOLIC DISORDERS
3.1. PPARsasanuclearreceptorfamily
Peroxisomes are subcellular organelles that perform diverse
metabolic functions, including H2O2-derived respiration, β-
oxidationoffattyacids,andcholesterolmetabolism.Rodents
exposed to peroxisome proliferators lead to hepatocellular
hypertrophy, hyperplasia, and transcriptional induction of
fattyacid-metabolizingenzymesthatareregulatedinparallel
with peroxisome proliferation [29]. Peroxisome proliferators
may activate PPARs by binding directly to the receptors,
and the activated PPARs may regulate the expression of
genes involved in lipid metabolism and peroxisome prolif-
eration. Recent research on PPARs has moved toward their
pivotal roles comprising one family of nuclear receptors
[30]. Nuclear receptors, which are present in multicellular
organisms, directly control the expression of genes in
response to a wide range of developmental, physiological,
and environmental signals.
The PPARs of nuclear receptors mainly consist of three
subtypes (PPARα,P P A R γ,a n dP P A R δ/β). All three PPAR
isoforms possess similar structural and functional features.
Principally, four functional domains have been identiﬁed,
and are referred to as A/B, C, D, and E/F. The N-terminal
A/B domain contains ligand-independent activation func-
tion 1 (AF-1). The ligand-independent activation region
can confer constitutive activity on the receptor, and is
negatively regulated by phosphorylation [31]. The DNA-
binding domain (DBD) or C domain consists of two zinc
ﬁngers, and is directly involved with the binding of PPAR
to the peroxisome proliferator response element (PPRE)
in the promoter regions of target genes. PPREs are direct
repeat (DR)-1 elements consisting of two hexanucleotides
with the AGGTCA consensus sequence separated by a single
nucleotidespacer.Suchasequence,orasimilarone,hasbeen
found in numerous PPAR-inducible genes, including acyl-
CoAoxidase(ACO)andadipocytefattyacid-bindingprotein
(aP2)[32].TheDsiteisahingeregionandadockingdomain
for corepressors. The E/F domain or ligand-binding domain
(LBD) is responsible for ligand speciﬁcity and the activation
ofPPARbinding tothePPRE,whichincreasestheexpression4 PPAR Research
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Figure2:SignalingpathwaysactivatingPPARandregulatingthebiologicaleﬀectsofPPARindiﬀerentorgans.PPARactivitycanberegulated
by the direct binding of small lipophilic ligands. Ligand-unbound PPAR in the cytosol is associated with chaperons, and the association
changes the conformation of PPAR that allows for high-aﬃnity binding to the ligand. Ligand-bound PPAR forms a heterodimer with RXR,
and the PPAR-RXR heterodimer constructs the transcriptional machinery through the recruitment of coregulators. The transcriptional
machinery regulates gene expression by binding to speciﬁc DNA sequence elements, termed PPAR response elements (PPRE). PPARα is
strongly expressed in the liver, heart, and blood vessels, and regulates the expressions of genes related to lipid metabolism and inﬂammation
control. PPARγ exerts its eﬀects on insulin sensitivity and glucose homeostasis in adipocytes and skeletal muscles. PPARδ is expressed
ubiquitously, and controls the expressions of genes that are involved in glucose and lipid metabolism. FA: fatty acid; HDL: high-density
lipoprotein; VDL: very low-density lipoprotein; ABCA1: ATP-binding cassette transporter A1; UCP: uncoupling protein; TG: triglyceride.
of the targeted gene. Upon the binding of a speciﬁc ligand
to LBD of the E/F domain, the conformation of a PPAR is
altered and stabilized. The ligand-bound LBD results in the
recruitment of transcriptional coactivators, resulting in gene
transcription. Although three of the PPAR isoforms possess
similar structures, it is clear that these receptors perform
distinct functions according to the speciﬁc ligands and their
expression patterns in the tissues.
3.2. PPARsandtheirligands
Ligand-induced activation of the PPAR, by means of low-
aﬃnity binding to natural lipid ligands, stimulates an array
of molecular responses that aim at maintaining lipid and
glucose homeostasis. Ligand-unbound PPAR is associated
with chaperon in the cytosol, and the association induces
the PPAR to be held in a conformation that allows for high-
aﬃnity binding of the ligand [33]. The translocation of a
hydrophobic ligand into the cell is facilitated in intra- and
extracellular ﬂuids by intracellular lipid-binding proteins
(iLBPs) that are members of the family of fatty acid-binding
proteins (FABPs). The iLBPs with relatively small sizes
(15-16kDa) play important roles in the solubilization and
protection of ligands in aqueous spaces. Ligand-loaded iLBP
in the cytosol translocates into the nucleus by free diﬀusion,
and they form a short-lived complex with PPAR [34–36].
Ligand is then transferred to the PPAR, and the ligand-
bound PPAR forms a heterodimer with the partner nuclear
receptor, retinoid X receptor (RXRα). Upon binding to a
ligand, the conformation of PPAR is altered and stabilized,
andthePPAR-RXRheterodimerthenrecruitstranscriptional
coactivators [37–39]. The transcription machinery is bound
to PPRE, and directly controls the expression of the target
gene (Figure 2)[ 40].
PPARα was ﬁrst cloned from the rodent liver in 1990
[41], and PPARβ and PPARγ were ﬁrst identiﬁed in Xenopus
[42]. Several groups subsequently reported the cloning
of mammalian orthologs of PPARα,P P A R β,a n dP P A R γ.
Although PPARα and PPARγ are highly conserved across
species, PPARβ varies considerably between Xenopus andMin-Chul Cho et al. 5
mammals. The murine clone was named PPARδ because
of this divergence [43]. PPARα is predominantly expressed
in the liver, and is involved in peroxisome proliferation
and regulation of fatty acid catabolism. The expression of
PPARδ is ubiquitous and abundant in the brain, intestine,
skeletal muscle, spleen, macrophages, lung, and adrenals
[44]. PPARδ is activated by a large variety of ligands, and has
been implicated in developmental and metabolic regulation
in several tissues. PPARγ is expressed in adipose tissue,
promoting adipogenesis and increasing lipid storage. PPARγ
has at least two promoters, and results in the production
of two isoforms, 1 and 2. These isoforms are expressed in
a tissue-speciﬁc pattern. The PPARγ1 isoform is expressed
in the spleen, intestine, and white adipose tissue, while the
PPARγ2 is preferentially expressed in white and brown fat.
PPARγ2 is most abundantly expressed in fat cells, and plays
a pivotal role in fat cell diﬀerentiation and lipid storage
[45]. The distinct physiological roles of each subtype have
been shown to be determined by binding to a discrete set of
ligands. Although fatty acids could activate PPARs, PPARα
activity was induced by eicosanoids [46], cabaprostacyclin
[47], and nonsteroidal anti-inﬂammatory drugs (NSAIDs)
[48]. PPARδ w a sa c t i v a t e db ys e v e r a lp o l y u n s a t u r a t e df a t t y
acids [49] and eicosanoids [50]. PPARγ speciﬁcally binds
to thiazolidinediones (TZDs), a class of antidiabetic drugs.
Other PPARγ ligands include the natural prostaglandin
metabolite 15-deoxy-Δ12.14-prostaglandin J2(PGJ2), polyun-
saturated fatty acids, and NSAIDs such as ibuprofen and
indomethacin [51, 52].
3.3. Post-translationalregulationofPPARs
PPARs and other nuclear receptors modulate their tran-
scriptional activity via phosphorylation by various kinases,
including the mitogen-activated protein kinase (ERK MAPK
and p38 MAPK), protein kinase A and C (PKA and PKC),
AMP kinase (AMPK), and glycogen synthase kinase 3
(GSK3) [53]. Several mechanisms have been described to
explain the modulation of PPAR transcriptional function.
First, phosphorylation modulates the aﬃnity of PPARs for
their ligand, as well as the coactivator recruitment abilities of
PPARs. Although the main phosphorylation site of PPARγ
(Ser 112) is located far from the ligand-binding domain,
mutatedPPARγ (S112D)exhibitsadecreasedligand-binding
aﬃnity and decreased coactivator recruitment [54]. Second,
the phosphorylation of PPARs modulates binding to PPRE.
In gel retardation experiments, PPARα phosphorylation via
PKA enhances gene expression due to the stabilization of
the binding of PPARα to DNA [55]. Finally, phosphorylation
plays an important role in ubiquitination and proteasomal
catabolism of PPARs. Phosphorylation of the PPARγ AF-
1d o m a i nb yI F N γ-ERK-regulated serine phosphorylation
promotes the degradation of PPARγ by the ubiqutin-
proteasome-dependent degradation in response to ligand
activation [56]. PPARα is also degraded by the ubiquitin-
proteasome-dependent degradation. However, in contrast to
PPARγ, phosphorylation of PPARα induces the stabilization
of PPARα by reducing ubiquitination. The phosphorylation
and interaction of PPARα with a corepressor stabilize PPARα
protein by decreasing its ubiquitination in order to keep a
pool of PPARα available for ligand binding and activation
[57].
SUMOylationconsistsofthecovalentandreversiblecon-
jugation of small ubiquitin-related modiﬁers (SUMOs) to
target protein and regulate biological processes. The number
of known SUMO targets is growing, and SUMOylation of
PPARγ has recently been reported. SUMOylation of PPARγ
mainlyoccursatalysineresiduewithinaligand-independent
activating function domain (AF-1). PPARγ is SUMOylated
by SUMO-1 and PIAS proteins that function as E3 ligases
[58]. Potential SUMOylation sites of PPARγ include K77
(equivalent to K107 of PPARγ2) and K365. SUMOylation
of PPARγ at K77 and K365 occurs in a ligand-dependent
manner. SUMOylation of K107 inhibits PPARγ-dependent
gene induction, but does not aﬀect transrepression, whereas
mutation of K365 eliminates the ability of agonist-activated
PPARγ t or e p r e s si N O Sa n dt ob er e c r u i t e dt oi t sp r o m o t e r
[59]. Phosphorylation at S112 of PPARγ2 promotes K107
SUMOylation and exerts more potent repressive eﬀects.
The SUMOylation-defective mutation of PPARγ at K77R
promotes adipocyte diﬀerentiation. The potential SUMOy-
lation site of PPARα has one K185 within the D region,
and PPARδ/β has one K104 in the C region, but in vivo
SUMOylation is speciﬁc for PPARγ among the PPARs [60].
Relatively few studies of post-translational regulation of
PPARs have been reported.
3.4. RoleofPPARligandsinmetabolicdisorders
The activation of PPARα upregulates the expressions of
several catabolic enzymes that are involved in mitochondrial
and peroxisomal β-oxidation and microsomal ω-oxidation,
as well as in the transcriptional regulation of genes that
are necessary for the maintenance of the redox balance
during the oxidative catabolism of fatty acids. The deriva-
tives from fatty acids and ﬁbrates, including gemﬁbrozil,
fenoﬁbrate, coﬁbrate, bezaﬁbrate, and ciproﬁbrate, can acti-
vate PPARα. These ﬁbrates are used in the treatment of
hypertriglyceridemia. PPARα agonists fundamentally regu-
late β-oxidation of fatty acids, and promote the expres-
sion of cytochrome P450 enzymes, which catalyze the ω-
hydroxylation of fatty acid [61]. WY14,643, a well-known
speciﬁc PPARα agonist, increases fatty acid oxidation by
increasing the expressions of peroxisomal and mitochon-
drial fatty acid β-oxidation enzymes. WY14,643 reduces
liver insulin resistance more eﬃciently than muscle insulin
resistance by normalizing the circulating triglyceride levels
a n db l o o dg l u c o s el e v e l si nl i p o a t r o p h i cm i c e[ 62]. PPARα
agonists also activate the expression of apolipoprotein A-1
(ApoA-1)andATP-bindingcassettetransporterA1(ABCA1)
[63, 64]. The increased ApoA-1 and ABCA1 proteins
enhance cholesterol eﬄux by the reverse cholesterol trans-
port (RCT) pathway. In addition, PPARα agonists have anti-
inﬂammatory eﬀects in vascular cells. WY14,643 or bezaﬁ-
brate induces PPARα-mediated inhibition of osteopontin
(OPN) expression in human macrophages of atherosclerotic
lesions, where they are abundantly synthesized. Bezaﬁbrate
signiﬁcantly decreases OPN plasma levels in type 2 diabetic6 PPAR Research
patients [65]. Therefore, the PPARα agonist reduces the
progression of atherosclerosis and decreases the incidence
of coronary heart disease [66]. However, ﬁbrates are con-
traindicated in patients with renal insuﬃciency, gallstones,
abnormal liver function tests, and pregnancy [67].
The activation of PPARγ promotes the storage of fat
by increasing adipocyte diﬀerentiation and enhancing the
transcription of genes that are important for lipogenesis.
The activation of either PPARα or PPARγ in macrophages
promotes the cellular eﬄux of phospholipids and cholesterol
in the form of high-density lipoproteins by upregulating
the expression of the liver X-receptor (LXR), an oxysterol-
activatednuclearhormonereceptorthatincreasesexpression
of the lipid transporter ABCA1 (ATP-binding cassette,
subfamily A, member 1) [68]. PPARγ has been the focus
of intense research during the past decade because ligands
for this receptor have emerged as potent insulin sensitizers
that can be used in the treatment of type 2 diabetes [69].
Increased levels of circulating free fatty acids and lipid accu-
mulation in non-adipose tissue have been implicated in the
development of insulin resistance. This situation is improved
by the PPARγ agonist, which promotes fatty acid storage
in fat depots and regulates the expression of adipocyte-
secreted hormones that impact glucose homeostasis [70].
The net result of the pleiotropic eﬀects of the PPARγ agonist
is improvement of insulin sensitivity, although undesired
side eﬀects limit the utility of this therapy. In fact, TZD,
a synthetic agonist of PPARγ, appears to be ideally suited
for the treatment of this cluster of metabolic abnormalities,
which has been termed the insulin resistance or cardio-
vascular dysmetabolic syndrome as a whole [71]. Two
compounds in this class are currently approved for use in the
United States. They are Rosiglitazone (Avandia), approved
by the US Food and Drug Administration (FDA) in May
1999, and Pioglitazone (Actos), which was approved in July
1999. Historically, the ﬁrst agent in this class, Troglitazone
(Rezulin), was marketed in the United States from March
1997 to March 2000. Troglitazone was banned because the
FDA determined that the risk of idiosyncratic hepatoxicity
associatedwithTroglitazonetherapyoutweigheditspotential
beneﬁts [72, 73].
The activation of PPARδ in macrophages also upreg-
ulates the expression of the ABCA1 transporter. Recent
evidenceindicatesthatPPARδ canalsopromotecellularlipid
accumulation by increasing the expressions of genes that are
involved in lipid uptake, and by repressing key genes that are
involved in lipid metabolism, inﬂammation, atherosclerosis,
obesity, fertility, and cancer [74, 75]. Several 14- to 18-
carbon saturated fatty acids as well as 16- to 20-carbon
polyunsaturated fatty acids are screened as PPARδ-binding
chemicals in ligand screening and competition binding
assays [50, 76, 77]. As physiological ligands of PPARδ,
these fatty acids or eicosanoids are unsettled. However,
Chawla et al. hypothesized that PPARδ acts as a lipid
sensor, where fatty acids derived from very-low-density
lipoprotein (VLDL) can activate PPARδ [78]. A PPARδ-
speciﬁc agonist, GW501516, decreases plasma triglyceride
levels in obese monkeys, raises high-density lipoprotein
levels, and prompts the initiation of clinical trials to assess
its eﬃcacy in hyperlipidemic patients [79]. GW501516 also
attenuates weight gain and insulin resistance in mice fed
high-fat diets by increasing the expressions of genes that
promote lipid catabolism and mitochondrial uncoupling in
skeletal muscle, thereby increasing β-oxidation of the fatty
acids in skeletal muscle [80]. PPARδ agonists also have
anti-inﬂammatory properties. The PPARδ agonist inhibits
LPS-inducible genes, such as COX-2 and iNOS in murine
peritoneal macrophages [81]. These reports indicate that the
PPARδ-speciﬁc agonist is a potential therapeutic interest for
the treatment of metabolic disorder.
4. VARIOUS STRATEGIES FOR SAFER PPAR
MODULATORS
Each PPAR subtype regulates a distinct metabolic pathway,
and the agonists of each of the PPAR subtypes have
distinct eﬀects with undesired side eﬀects such as weight
gain, hepatotoxicity, and heart failure. In the case of the
TZD class as PPARγ agonists, the major side eﬀect is
weight gain. A Pro12Ala substitution in PPARγ2d e c r e a s e s
PPARγ activity, BMI, and insulin resistance [82]. Because
of these undesirable eﬀects caused by PPARγ agonists, new
therapeutic solutions have been investigated in order to
reduce their side eﬀects. Various compounds have been
reported to be PPAR antagonists, including Bisphenol A
diglycidyl ether (BADGE), PD068235, LG100641, GW9662,
SR-202, GW6741, and Compound A and B [83]. A potent
selective PPARγ antagonist, GW9662, does not recruit PPAR
coactivators such as SRC-1 and p300, and it suppresses
rosiglitazone-induced adipocyte diﬀerentiation in 3T3-L1
adipocytes. GW9662 prevents high-fat diet-induced obesity
without aﬀecting food intake, and has no eﬀect on high-fat
diet-induced glucose intolerance [84]. The phosphonophos-
phate SR-202, a PPARγ antagonist, inhibits BRL 49653-
mediated recruitment of SRC-1 and troglitazone-induced
transcriptional activity. SR-202 inhibits PPARγ-induced
adipocyte diﬀerentiation of 3T3-L1 and prevents weight
gain and adipose tissue deposition in mice given a standard
diet or high-fat diet. In addition, SR-202 markedly reduces
hyperglycemia and hyperinsulinemia in ob/ob mice [85].
Af e wP P A R α antagonists have been reported, but in vivo
datahavenot beendisclosed. SeveralPPARγ antagonistsmay
have therapeutic availability as antiobesity drugs. However,
further studies of the molecular eﬀects of PPARγ antagonists
are necessary.
Thecombinationagoniststrategy,whichusesacombina-
tion of agonists, has been designed to activate each receptor
subtype. In terms of its pharmacological aspects, this strat-
e g ym a yp r o v i d em o r ee ﬃcacious eﬀects and more safety
for undesired side eﬀects. The possible combinations are
PPARα/γ dual agonist, PPARγ/δ dual agonist, PPARα/δ dual
agonist,andPPARpan(PPARα/γ/δ)agonist.Theinitialcom-
bination agonist strategy was focused on the development of
PPARα/γ dual agonists. PPARγ agonists such as rosiglitazone
and pioglitazone provide undesired side eﬀects of TZDs,
including weight gain. By contrast, PPARα agonists such as
ﬁbrate decreased adiposity through the stimulation of lipid
oxidation. Dual PPARα/γ stimulation with a combinationMin-Chul Cho et al. 7
of rosiglitazone and fenoﬁbrate in type 2 diabetic patients
eﬀectively improved the atherogenic dyslipidemic proﬁle,
which plays a key role in the occurrence of cardiovascular
mortality [86]. Applications of structurally various PPARα/γ
dual agonists have recently been reported. Among these
dual PPARα/γ agonists, compounds belonging to the glitazar
class have been advanced to clinical development (Phases
II and III). These PPARα/γ dual agonists commonly reduce
triglycerides and total cholesterol, increase HDL levels, and
consequently improve insulin sensitivity. However, the use
of a few PPARα/γ dual agonists, including muraglitazar,
tesaglitazar, ragaglitazar, farglitazar, TAK559, and KRP297,
has been discontinued due to various safety liabilities
compared to selective agonists. All glitazars signiﬁcantly
increase weight gain and edema, because of higher PPARγ
aﬃnitythanPPARαaﬃnityalthoughtheiraﬃnityforPPARα
is higher than ﬁbrates. Muraglitazar increases cardiovascular
risks, tesaglitazar impairs glomerular ﬁlteration rate, and
some have carcinogenic eﬀects in mice [87]. The safety
liabilities may be the result of their imbalanced activities on
PPARγ and PPARα. Therefore, the best solution would be to
screen candidates with appropriate aﬃnity for PPARα and
selective PPARγ-modulating activity [88].
Both PPARγ and PPARδ play important roles in glucose
and lipid metabolism. A PPARγ/δ dual agonist with a prop-
erly controlled γ/δ ratio could attenuate undesired weight
gain, improve insulin sensitivity, and stimulate fatty acid oxi-
dation. The dual PPARγ/δ agonist (R)-3-{2-ethyl-4-[3-(4-
ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic
acid has been shown to lower the glucose level and cause less
weight gain than rosiglitazone in hyperglycemic male Zucker
diabetic fatty (ZDF) rats [89]. The other dual PPARγ/δ
agonist, (R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-
butoxy]-2-ethyl-phenyl}-propionic acid, improves insulin
sensitivity and reverses diabetic hyperglycemia with less
weight gain relative to rosiglitazone in female ZDF rats
[90]. PPARα/δ dual agonists (T659 and Compound 24)
have recently been reported. T659 has had beneﬁcial eﬀects
on HDL-C in experimental primates [91]. Compound 24
has also shown signiﬁcant eﬀects on HDL-C, TG, and FFA
levels in male hApoA1 transgenic mice [92]. PPARα/δ dual
agonists may improve hyperlipidemia, insulin resistance,
and risk of atherosclerosis. The development of PPARα/δ
and PPARγ/δ dual agonists is currently being pursued.
Another strategy to reduce the adverse eﬀects of previous
PPARγ agonists is the identiﬁcation of partial agonists, also
referred to as selective PPARγ modulators (SPPARγMs).
SPPARγMs are PPARγ ligands with insulin-sensitizing
activity and lower stimulation of adipogenesis. Because
SPPARγMs bind to the ligand-binding pocket of the PPARγ
receptor in distinct manners, SPPARγM-bound PPARγ
induces the displacement of the diﬀerential cofactor and
the speciﬁc gene expression in a tissue-speciﬁc manner.
Although several PPARγ agonists have been classiﬁed as
SPPARγMs, the majority of these synthetic ligands remain
to be characterized at the molecular level, and need to
be evaluated in in vivopreclinical models to assess their
relationships with weight gain [93]. Halofenate (HA) and
PA-082, new SPPARγMs, were recently developed. HA
causes displacement of corepressors (N-CoR and SMRT),
but does not cause eﬃcient recruitment of coactivators
(p300, CBP, and TRAP 220). Moreover, HA selectively
regulates the expression of multiple PPARγ responsive
genes in 3T3-L1 adipocytes, and has acute antidiabetic
properties in diabetic ob/ob mice [94]. The isoquinoline
derivative PA-082, a prototype of a novel class of non-TZD
partial PPARγ agonists, causes preferential recruitment of
PPARγ-coactivator-1α (PGC1α) to the receptor compared
with rosiglitazone. PA-082 antagonizes rosiglitazone-driven
transactivation and TG accumulation in C2H10T1/2
mesenchymal stem cells. However, PA-082 induces mRNAs
of genes that encode components of insulin signaling
pathways. It also facilitates glucose uptake and insulin
signaling in mature adipocytes [95]. The functional study of
SPPARγMs will provide more information about eﬀective
antidiabetic agents to reduce the side eﬀects of weight gain.
The PPARpan agonists can activate all three PPAR
subtypes, and they can potentially exert various eﬀects
on metabolic disorders such as insulin resistance, obesity,
dyslipidemia, and hypertension. The well-known lipid-
lowering bezaﬁbrate is the ﬁrst clinically-tested PPARpan
agonist.ThoughbezaﬁbrateisaPPARligandwitharelatively
low potency, it considerably raises HDL cholesterol, reduces
triglycerides, improves insulin sensitivity, and reduces blood
g l u c o s el e v e l s[ 96]. GW677954, a novel PPARpan agonist,
is being investigated in Phase II trials for the treatment of
metabolic disorders [97]. PLX-204 and GW-625019 are also
progressing in Phase I trials for the treatment of metabolic
disorders. In addition, LY-465608, DRF-11605, CS-204, and
DRL-11605 are under investigation, and may be potent ther-
apeutic agents for the treatment of metabolic disorders [88].
5. TECHNOLOGIES TO DISCOVER NEW PPAR
MODULATORS
The development of new technology to discover PPAR
modulator is signiﬁcant in functional study of the nuclear
receptors and new potent drug discovery. In general, trans-
activation and chimeric receptor transactivation assays have
beenusedascell-basedmethodsemployingmammaliancells
for the screening of new PPAR modulators. Cell-based assays
provide a more physiological relevance, but these assays are
costly, time-consuming, and diﬃcult to apply to automated
systemsusedforhigh-throughputscreening(HTS).Recently,
Chen et al. introduced a yeast-based method for screening
PPAR modulators [98]. Cell-free assays for the screening of
PPAR modulators have been developed in numerous forms.
The X-ray crystal structure study revealed that the human
apo-PPARγ ligand-binding domain (LBD) has a large bind-
ing pocket, which may explain the diversity of the PPARγ
ligands [99]. When binding to speciﬁc ligands in LBD, PPAR
changes its conformation. Glutamate and lysine residues that
arehighlyconservedinLBDsofPPARforma“chargeclamp”
that contacts the backbone atoms of the LXXLL helices of
coactivators such as steroid receptor coactivator-1 (SRC-
1). In the case of SRC-1, four consecutive LXXLL motifs
make identical contacts with both subunits of a PPAR-RXR
heterodimer [100]. Such allosteric conformational changes8 PPAR Research
promote the recruitment of nuclear receptor coactivators
and eﬀectively stimulate the transcription of their target
genes.DiﬀerentPPARligandsmayelicitdistinctdownstream
biological eﬀects due to unique conformational changes in
the nuclear receptor.
A cell-free competition radioreceptor assay using com-
petitive interaction between a recombinant PPAR protein
and a radioisotope-labeled ligand in the presence of com-
petitor ligands has been reported previously (Figure 3(a))
[101, 102]. The coactivator-dependent receptor ligand assay
(CARLA) has been reported as a cell-free assay based on
the interaction between PPAR and the coactivator. CARLA
is based on the recruitment of a transcriptional coactivator
by changes in the conformation of ligand-bound PPAR
(Figure 3(b)). In presence of PPAR ligands,35S-labeled SRC-
1 has stronger interaction with GST-fused PPAR proteins
immobilized on glutathione Sepharose beads. Autoradio-
grams and the quantiﬁcation of the eﬀect of candidates are
dependent on the retention of SRC-1 by the GST-PPAR LBD
[76]. The major advantage of CARLA is that it does not
require radioactive labeling of candidate modulators, which
makes it possible to screen a large number of compounds
with this assay; this has simultaneous economic advantages
in terms of materials and time.
Scintillation proximity has been developed as a tool for
measuring the interaction between a receptor and a ligand.
The scintillation proximity assay (SPA) bead is impregnated
with a scintillant and coated with a capture molecule
such as streptavidin. After preincubation of SPA beads and
biotinylated PPAR LBD, radiolabeled ligands were added to
a complex of SPA bead-PPAR LBD. Unbound free ligands
were eliminated from the SPA-PPAR complex. When SPA-
bead and radiolabeled ligands come into close proximity,
radioactive counts are determined by the β emission from
the radioisotope to be absorbed by the scintillant, which
will then shift this energy to produce light (Figure 3(c))
[103, 104]. The advantages of the SPA are as follows:
low cost, high sensitivity, high reliability, and simplicity,
that is, no separation step is required. The simplicity of
SPA is an important beneﬁt in its application to HTS.
However, unsuitability for kinetic determination and the
limitednumberofusefulisotopeswereperceivedaspotential
disadvantages.
Fluorescence has been considered as an analytical tech-
nique with which to study for the detection and quantitation
of interacting molecules. There are several advantages to
this technique, including high sensitivity, the relative ease
of handling and disposal compared to radioactivity, and
the diversity of available ﬂuorophores. Thus, ﬂuorescence
resonance energy transfer (FRET) has been applied in
the probing of molecular interactions [105]. As shown
in Figure 3(d), GST-PPAR LBD was indirectly linked to
Eu(K) through an anti-GST antibody, which was covalently
linked to Eu(K). Coactivator was also indirectly linked
to XL665 through a streptavidin (SA)-biotin adapter. The
conformationalchangeofPPARbythePPARagonistinduces
the recruitment of coactivator, and the interaction between
PPAR and a coactivator will result in the close proximity of
the ﬂuorescence donor and acceptor. Consequently, the ﬂu-
orescence donor (anti-GST-Eu(K)) is excited, and inputted
energy will be transferred to the acceptor (streptavidin-
XL665). Homogenous time-resolved ﬂuorescence (HTRF)
energy transfer technology takes advantage of ﬂuorescence,
as well as the homogenous and time-resolved detection
mode. These speciﬁcities of HTRF enable it to overcome
most of the drawbacks encountered in FRET [106].
Previous cell-free methods with which to screen PPAR
agonists have used isotope or ﬂuorescence labeling agonists
or proteins. We established very simple ELISA systems
based on the ligand-dependent binding between PPAR and
coactivators.In brief,the puriﬁed recombinant LXXLLmotif
of coactivators was applied into a 96-well plate, and E.
coli lysates containing recombinant PPAR proteins were
then added with candidate PPAR agonists. The complex
consisting of PPAR and coactivator was then identiﬁed with
the anti-PPAR antibody (Figure 3(e)). Major advantages of
this simple method are its simplicity and its low cost, as these
systems do not require any labeling of candidate modulators
and proteins. This makes it possible to screen a large number
of compounds, with simultaneous economic advantages in
terms of materials and time. On the other hand, this method
has relatively low sensitivity and has to use a suitable anti-
PPAR antibody [107–109].
In the 1980s, surface plasmon resonance (SPR) and
related techniques that exploited evanescent waves were
applied for the study of biological and chemical interactions.
SPR technology has also been successfully employed to study
the interactions between ligands and nuclear receptors [110–
112],theeﬀectsofligand-bindingonnuclearreceptordimer-
ization [113], and ligand screening based on interactions
between ligand-bound nuclear receptors and coactivators
[114, 115]( Figure 3(f)). In the interaction analysis between
PPAR LBD and ligand, PPAR LBD is immobilized on the
sensor chip by a standard primary amine-coupling reaction,
and the ligand is injected over the immobilized PPAR
LBD. In the investigation of ligand binding on receptor
dimerization, the partner nuclear receptor is immobilized
on the sensor chip by the standard amine-coupling reaction,
and the nuclear receptor pre-incubated with its ligand is
injected over the immobilized partner nuclear receptor.
In ligand screening based on interactions between ligand-
bound nuclear receptors and coactivator, the coactivator or
LXXLL peptide is immobilized on the sensor using same
methods, and the nuclear receptor that was preincubated
with a candidate chemical is injected over the immobilized
coactivator peptide. The association (ka) and dissociation
(kd) rate constants and the dissociation equilibrium con-
stants (kDs) for the bindings were determined using the
Biacore biosensor. The binding responses in resonance units
(RUs) were continuously recorded, and were presented
graphically as a function of time. SPR technology has the
advantages in that it requires no labeling, can be performed
in real-time, and utilizes noninvasive measurements.
6. SUMMARY
Obesity mainly reﬂects an increased adipose cell size, an
increased adipocyte cell number, and an imbalance betweenMin-Chul Cho et al. 9
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Figure 3: Various cell-free assays to discover PPAR modulator. A. Competition radioreceptor assays are performed by incubating
recombinant PPAR protein and radioisotope-labeled ligand in the presence of competitor ligands. Bound ligands are separated from
free forms by ﬁltration. The amount of bound radioisotope-labeled ligand is determined by liquid scintillation counting. B. Coactivator-
dependent receptor ligand assays (CARLAs) based on the recruitment of a coactivator due to a conformational change of speciﬁc
ligand-bound PPAR. CARLA is carried out by incubating GST-PPAR and radioisotope-labeled coactivator with a ligand candidate or by
incubatingradioisotope-labeledPPARandGST-coactivatorwithligandcandidates.Theamountofligand-boundPPAR-coactivatorcomplex
is determined by pull-down assay. C. In the scintillation proximity assay (SPA), the receptor-ligand complex is bound to the SPA bead
through interaction between the biotinylated receptor and the streptavidin moiety located on the surface of the SPA bead. Because no
separation step is required, SPA has beneﬁts in its application to HTS. D. In the ﬂuorescence resonance energy transfer (FRET)-based in
vitro recruitment assay, GST-PPAR LBD proteins are indirectly linked to EU cryptate, (Eu)K, through (Eu)K-labeled anti-GST antibody,
α-GST-(Eu)K. Puriﬁed recombinant coactivator is biotinylated, and is indirectly linked to XL665, which is produced only when there is a
ligand-induced change in receptor conformation that results in binding to the coactivator. The extent of the FRET is measured as a ratio
of 665nm/620nm X 10,000. E. A simple ELISA based on binding between PPAR and coactivators. The ligand unbound-PPAR weakly
binds to the LXXLL motifs of coactivator, whereas ligand loaded-PPAR strongly binds to the LXXLL motifs of coactivator due to the
conformational change of PPAR by speciﬁc agonists. This binding is detected by a speciﬁc anti-PPAR antibody, followed by horseradish
peroxidase-conjugated secondary antibody. F. Schematic representation of SPR technology. One of the interacting partners is immobilized
on a gold or waveguide layer of the sensor chip using the standard amine-coupling protocol. The other ﬂows over the surface of the sensor
chip, allowing interaction with the immobilized interacting partners. The interaction of immobilized partners with interacting molecules
gives rise to an increase in mass. The refractive index and the angle of reﬂected light is thereby changed. As soon as the injection is stopped,
the complex is washed with a washing buﬀer. The interacting molecules are dissociated from the immobilized interacting partner, resulting
in a decrease in the signal due to a shift in the angle of the reﬂected light to its original position.
energy intake and energy expenditure. Excess body fat is
associatedwithmetabolicdisorders.Asamoleculardrugtar-
getformetabolicdisorders,theactivationofPPARbyspeciﬁc
ligands has many beneﬁcial clinical eﬀects in the improve-
ment of glucose and lipid homeostasis. The PPARs mainly
consist of three subtypes (PPARα,P P A R γ,a n dP P A R δ),
and all three PPAR isoforms possess similar structural
and functional features involving glucose metabolism, lipid
metabolism, and energy balance. PPARs directly modulate
gene expression upon binding to speciﬁc ligands transferred
into PPAR via iLBP-mediated translocation. PPAR agonists
play an important role in therapeutic aspects of metabolic
disorders, whereas undesired eﬀects for the existing PPAR
agonists prescribed as therapeutic agents have been reported.
To discover new PPAR modulators with more eﬃcacious
eﬀects and more safety against undesired side eﬀects, a novel
PPAR antagonist or the combination of agonists such as
PPARα/γ dual agonist, PPARγ/δ dual agonist, PPARα/δ dual
agonist,andPPARpan(PPARα/γ/δ)agonisthasbeenapplied
to activate each receptor subtype and selective PPARγ mod-
ulators (SPPARγMs). In addition, various technologies have
been developed in attempts to discover PPAR modulators as
therapeutic agents for the treatment of metabolic disorders.
Because cell-based assays have more physiological relevance,
the transactivation assay, chimeric receptor transactivation,
and yeast two-hybrid methods have also been used. Since
cell-free assays are based on direct interaction between PPAR
and their speciﬁc ligands, a new concept for competing
radioreceptor assays has been developed by making the best
use of competitive interactions between recombinant PPAR
protein and radioisope-labeled ligands. Later, cell-free assays
(CARLA and SPA) were developed based on conformational
changes in PPARs caused by their ligands, and the simplicity
of SPA permitted application to high-throughput screening
(HTS). Radioisotope-free assays like FRET (HTRF), ELISA,
and SPR methods are relatively simple in terms of handling
and disposal. Thus, HTRF and SPR assays can be applied to
a homogenous and time-resolved detection mode.
Interestingly, prior to the discovery of the PPARα,i tw a s
reported that Wy-14,643, a well-known synthetic agonist of
PPARα,decreasedserumcholesterolandtriglyceridelevelsin
mice [116]. TZD derivatives, well-known synthetic agonists
of PPARγ, were reported as antidiabetes agents prior to the
discovery of the PPARγ [117, 118]. An antidiabetes agent,Min-Chul Cho et al. 11
pioglitazone, a TZD derivative, has recently been shown
to bind speciﬁcally to a protein named mitoNEET [119].
These studies of PPAR, PPAR modulators, and technologies
to discover PPAR modulators will elicit the development of
drugs with more eﬃcacious eﬀects and more safety for the
treatment of metabolic disorders.
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